Literature DB >> 30234392

The dawn of precision medicine in HIV: state of the art of pharmacotherapy.

Ying Mu1, Sunitha Kodidela2, Yujie Wang2, Santosh Kumar2, Theodore J Cory1.   

Abstract

INTRODUCTION: Combination antiretroviral therapy (ART) reduces viral load to under the limit of detection, successfully decreasing HIV-related morbidity and mortality. Due to viral mutations, complex drug combinations and different patient response, there is an increasing demand for individualized treatment options for patients. AREAS COVERED: This review first summarizes the pharmacokinetic and pharmacodynamic profile of clinical first-line drugs, which serves as guidance for antiretroviral precision medicine. Factors which have influential effects on drug efficacy and thus precision medicine are discussed: patients' pharmacogenetic information, virus mutations, comorbidities, and immune recovery. Furthermore, strategies to improve the application of precision medicine are discussed. EXPERT OPINION: Precision medicine for ART requires comprehensive information on the drug, virus, and clinical data from the patients. The clinically available genetic tests are a good starting point. To better apply precision medicine, deeper knowledge of drug concentrations, HIV reservoirs, and efficacy associated genes, such as polymorphisms of drug transporters and metabolizing enzymes, are required. With advanced computer-based prediction systems which integrate more comprehensive information on pharmacokinetics, pharmacodynamics, pharmacogenomics, and the clinically relevant information of the patients, precision medicine will lead to better treatment choices and improved disease outcomes.

Entities:  

Keywords:  Antiretroviral therapy; pharmacodynamics; pharmacogenetic; pharmacokinetics; precision medicine; therapeutic monitoring

Mesh:

Substances:

Year:  2018        PMID: 30234392      PMCID: PMC6291855          DOI: 10.1080/14656566.2018.1515916

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  160 in total

1.  A new classification for HIV-1.

Authors:  E A Berger; R W Doms; E M Fenyö; B T Korber; D R Littman; J P Moore; Q J Sattentau; H Schuitemaker; J Sodroski; R A Weiss
Journal:  Nature       Date:  1998-01-15       Impact factor: 49.962

Review 2.  Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor.

Authors:  Mamta Sharma; Louis D Saravolatz
Journal:  J Antimicrob Chemother       Date:  2012-10-25       Impact factor: 5.790

3.  Brief Report: High Peak Level of Plasma Raltegravir Concentration in Patients With ABCB1 and ABCG2 Genetic Variants.

Authors:  Kiyoto Tsuchiya; Tsunefusa Hayashida; Akinobu Hamada; Shinichi Oka; Hiroyuki Gatanaga
Journal:  J Acquir Immune Defic Syndr       Date:  2016-05-01       Impact factor: 3.731

4.  Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome.

Authors:  C Grunfeld; M Pang; W Doerrler; J K Shigenaga; P Jensen; K R Feingold
Journal:  J Clin Endocrinol Metab       Date:  1992-05       Impact factor: 5.958

5.  Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26.

Authors:  Hiroyuki Gatanaga; Tsunefusa Hayashida; Kiyoto Tsuchiya; Munehiro Yoshino; Takeshi Kuwahara; Hiroki Tsukada; Katsuya Fujimoto; Isao Sato; Mikio Ueda; Masahide Horiba; Motohiro Hamaguchi; Masahiro Yamamoto; Noboru Takata; Akiro Kimura; Takao Koike; Fumitake Gejyo; Shuzo Matsushita; Takuma Shirasaka; Satoshi Kimura; Shinichi Oka
Journal:  Clin Infect Dis       Date:  2007-09-24       Impact factor: 9.079

Review 6.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing.

Authors:  R S Gammal; M H Court; C E Haidar; O F Iwuchukwu; A H Gaur; M Alvarellos; C Guillemette; J L Lennox; M Whirl-Carrillo; S S Brummel; M J Ratain; T E Klein; B R Schackman; K E Caudle; D W Haas
Journal:  Clin Pharmacol Ther       Date:  2015-11-09       Impact factor: 6.875

7.  Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice.

Authors:  R M M Cleijsen; M E van de Ende; F P Kroon; F Verduyn Lunel; P P Koopmans; L Gras; F de Wolf; D M Burger
Journal:  J Antimicrob Chemother       Date:  2007-08-17       Impact factor: 5.790

8.  Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.

Authors:  Jeffrey L Lennox; Raphael J Landovitz; Heather J Ribaudo; Ighovwerha Ofotokun; Lumine H Na; Catherine Godfrey; Daniel R Kuritzkes; Manish Sagar; Todd T Brown; Susan E Cohn; Grace A McComsey; Francesca Aweeka; Carl J Fichtenbaum; Rachel M Presti; Susan L Koletar; David W Haas; Kristine B Patterson; Constance A Benson; Bryan P Baugh; Randi Y Leavitt; James F Rooney; Daniel Seekins; Judith S Currier
Journal:  Ann Intern Med       Date:  2014-10-07       Impact factor: 25.391

9.  Host genetic influences on highly active antiretroviral therapy efficacy and AIDS-free survival.

Authors:  Sher L Hendrickson; Lisa P Jacobson; George W Nelson; John P Phair; James Lautenberger; Randall C Johnson; Lawrence Kingsley; Joseph B Margolick; Roger Detels; James J Goedert; Stephen J O'Brien
Journal:  J Acquir Immune Defic Syndr       Date:  2008-07-01       Impact factor: 3.731

10.  Prediction of plasma efavirenz concentrations among HIV-positive patients taking efavirenz-containing combination antiretroviral therapy.

Authors:  Sung-Hsi Huang; Shu-Wen Lin; Sui-Yuan Chang; Ya-Ting Lin; Chieh Chiang; Chin-Fu Hsiao; Hsin-Yun Sun; Wen-Chun Liu; Yi-Ching Su; Chien-Ching Hung; Shan-Chwen Chang
Journal:  Sci Rep       Date:  2017-11-23       Impact factor: 4.379

View more
  4 in total

Review 1.  Host-Directed Antiviral Therapy.

Authors:  Naveen Kumar; Shalini Sharma; Ram Kumar; Bhupendra N Tripathi; Sanjay Barua; Hinh Ly; Barry T Rouse
Journal:  Clin Microbiol Rev       Date:  2020-05-13       Impact factor: 26.132

Review 2.  Evaluating emtricitabine + rilpivirine + tenofovir alafenamide in combination for the treatment of HIV-infection.

Authors:  Ying Mu; Michelle Pham; Anthony T Podany; Theodore J Cory
Journal:  Expert Opin Pharmacother       Date:  2020-01-20       Impact factor: 3.889

3.  A Link Between Methylglyoxal and Heart Failure During HIV-1 Infection.

Authors:  Prasanta K Dash; Fadhel A Alomar; Jesse L Cox; JoEllyn McMillan; Bryan T Hackfort; Edward Makarov; Brenda Morsey; Howard S Fox; Howard E Gendelman; Santhi Gorantla; Keshore R Bidasee
Journal:  Front Cardiovasc Med       Date:  2021-12-14

4.  Chemical exchange saturation transfer for detection of antiretroviral drugs in brain tissue.

Authors:  Aditya N Bade; Howard E Gendelman; JoEllyn McMillan; Yutong Liu
Journal:  AIDS       Date:  2021-09-01       Impact factor: 4.632

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.